ReviewBreast cancer research and treatment2026
SERENA-6 and the regulatory limits of radiologic progression in modern oncology.
Review in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence of real-time molecular monitoring has challenged traditional oncology paradigms, where radiologic progression has historically represented the primary trigger for therapeutic intervention. The SERENA-6 clinical trial introduced a novel treatment approach by adapting therapy based on ctDNA-detected molecular progression before radiologic progression in patients with HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The trial has prompted important discussion regarding the integration of molecular biomarkers into treatment decision-making and regulatory frameworks.
methodsWe reviewed the ODAC deliberations, regulatory discussions, published data, and expert perspectives surrounding SERENA-6 to examine the clinical, scientific, and regulatory implications of ctDNA-guided treatment adaptation and molecularly adaptive trial designs.
resultsThe SERENA-6 trial demonstrated significant improvements in progression-free survival, durable disease control, and quality of life outcomes. However, important considerations remain regarding the optimal timing of treatment adaptation, evidence required to support molecularly guided switching strategies, interpretation of crossover and survival outcomes, and the regulatory evaluation of adaptive precision oncology trials.
conclusionAs oncology transitions toward biologically driven treatment strategies, new clinical and regulatory frameworks are needed to define when molecular alterations should become actionable. SERENA-6 challenges the traditional reliance on radiologic progression as the sole trigger for therapeutic intervention and provides important lessons for the future development and evaluation of molecularly adaptive precision oncology strategies beyond breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.